Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Announces Allowance of Two New RHB-104 Patents Ahead of Top-Line Phase III Results for Crohn’s Disease
RedHill has received Notices of Allowance for two new patents covering RHB-104 in the U.S. and Europe which are expected to be valid until at least 2029, once granted   Top-line results from the first Phase III study with RHB-104 for Crohn’s disease are expected to be announced in the coming weeks  ...
View HTML
Toggle Summary RedHill Biopharma Announces U.S. Co-Promotion Agreement with Napo Pharmaceuticals for HIV/AIDS Anti-Diarrheal Drug Mytesi®
RedHill has been granted the exclusive right to co-promote Mytesi ® (crofelemer 125 mg delayed-release tablets) in the U.S. to certain gastroenterologists and primary care physicians for the approved indication in people living with HIV/AIDS by Napo Pharmaceuticals , a subsidiary of Jaguar Health ...
View HTML
Toggle Summary RedHill Biopharma to Present Positive Phase II Results of BEKINDA® for IBS-D at Digestive Disease Week 2018
TEL-AVIV , Israel and RALEIGH, N.C. , May 30, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
View HTML
Toggle Summary RedHill Biopharma Announces New U.S. Patent for its Experimental Ebola Therapy
TEL-AVIV, Israel and RALEIGH, N.C. , May 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
View HTML
Toggle Summary RedHill Biopharma to Host Investor Webcast on RHB-104 for Crohn’s Disease on May 15
Last patient completed treatment for primary endpoint assessment in the Phase III study with RHB-104 for Crohn’s disease; Top-line results expected to be announced in approximately 3 months TEL-AVIV, Israel and RALEIGH, N.C. , May 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. ...
View HTML
Toggle Summary RedHill Biopharma Reports First Quarter 2018 Financial Results
Key Highlights: Top-line results from Phase III study with RHB-104 for Crohn’s disease (MAP US study) expected in approximately 3 months Top-line results from confirmatory Phase III study with TALICIA ® for H. pylori infection (ERADICATE Hp2 study) expected Q4/2018 Net revenues of $2.4 million and ...
View HTML
Toggle Summary RedHill Biopharma Announces Last Patient Assessed for Primary Endpoint in RHB-104 Phase III Study for Crohn’s Disease
Top-line results from the Phase III study with RHB-104 for Crohn’s disease are expected to be announced in approximately three months   Worldwide sales of Crohn’s disease therapies are estimated to exceed $10 billion in 2018   Top-line results from the confirmatory Phase III study with TALICIA ® ...
View HTML
Toggle Summary RedHill Biopharma Announces Enrollment of 300th Patient in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
Approximately 70% of the planned total of 444 patients have been enrolled in the ongoing confirmatory U.S. Phase III study with TALICIA ® for H. pylori infection (ERADICATE Hp2) RedHill expects to complete enrollment in Q3/2018 and announce top-line results in Q4/2018   The study is expected to ...
View HTML
Toggle Summary RedHill Biopharma to Host First Quarter 2018 Financial Results Conference Call on May 8, 2018
TEL-AVIV, Israel and RALEIGH, N.C. , May 01, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
View HTML
Toggle Summary RedHill Biopharma Provides Semi-Annual Business Update
TEL-AVIV, Israel and RALEIGH, N.C. , April 09, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ( Tel-Aviv Stock Exchange :RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...
View HTML